Trial Profile
A Phase I Clinical Trial Combining Nivolumab and Tumor Infiltrating Lymphocytes (TIL) for Patients With Advanced Non-Small Cell Lung Cancer
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 26 Jul 2023
Price :
$35
*
At a glance
- Drugs Nivolumab (Primary) ; T lymphocyte cell therapies (Primary) ; Aldesleukin; Cyclophosphamide; Fludarabine; Interleukin-2
- Indications Adenocarcinoma; Non-small cell lung cancer
- Focus Adverse reactions
- 18 Jul 2023 Status changed from active, no longer recruiting to completed.
- 01 Aug 2021 Primary endpoint (Rate of Dose Limiting Toxicity (DLT)) has been met as per the results published in the Nature Medicine
- 01 Aug 2021 Results published in the Nature Medicine